Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1S-1-acetoxychavicol acetate (ACA) is a naturally derived small molecule phenylpropanoid isolated from the rhizomes of Alpinia conchigera Griff. and Alpinia galanga (family Zingiberaceae). It is a research compound primarily investigated for its anticancer, antiviral, and anti-inflammatory properties. ACA's mechanism of action involves the inhibition of exportin-1 (XPO1/CRM1), which blocks the nuclear export of proteins and viral RNAs, and the inhibition of NADPH oxidase (Nox) and proteasomal chymotrypsin-like activity. These actions lead to the suppression of the NF-κB signaling pathway, induction of apoptosis, and cell cycle arrest at the G0/G1 phase. Preclinical studies have demonstrated its efficacy against various human tumor cell lines, including oral squamous cell carcinoma, non-small cell lung cancer (NSCLC), and breast cancer, as well as its potential in treating androgenetic alopecia and viral infections like HIV-1 and influenza.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1S-1-acetoxychavicol acetate.